Jardiance vs Metformin in Special Populations: Head-to-Head

Why Comparing These Two Drugs Actually Matters

Metformin has been the cornerstone of type 2 diabetes pharmacotherapy since the 1990s. Empagliflozin arrived in 2014 with a different mechanism and, a year later, landmark trial data that changed prescribing guidelines worldwide. Calling this a simple "A vs B" question misses the clinical reality: in many patients, the correct answer is both.

Specific populations need a clear tiebreaker. Patients with stage 3 CKD, established heart failure, obesity-related metabolic syndrome, older age, or high fracture risk each present prescribing trade-offs that are not obvious from A1C data alone.

Mechanisms at a Glance

Metformin works primarily by suppressing hepatic glucose output and improving peripheral insulin sensitivity, without stimulating insulin secretion. It does not cause hypoglycemia as monotherapy. Its action depends on intact organic cation transporter-1 (OCT1) function in the liver.

Empagliflozin blocks sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule of the kidney, forcing glucose and sodium excretion in urine. Glycemic lowering is therefore renal-dependent, which explains why efficacy declines as eGFR falls. The osmotic and natriuretic effects produce weight loss, blood pressure reduction, and the hemodynamic changes that appear to drive cardiovascular and renal benefits.

What the Numbers Look Like Side by Side

A1C lowering with either agent as monotherapy runs roughly 0.6% to 1.2% from baseline, depending on starting A1C. Head-to-head monotherapy data are sparse; most trials compared each agent against placebo or sulfonylureas. In a 24-week active-comparator study of empagliflozin 25 mg versus glimepiride, empagliflozin produced comparable A1C reduction with 2.2 kg weight loss and no hypoglycemia, which gives indirect context for its profile relative to oral agents [1].

Cardiovascular Disease: Jardiance Wins Clearly

For patients with established atherosclerotic cardiovascular disease (ASCVD), empagliflozin has a level of evidence that metformin cannot match in the modern sense.

EMPA-REG OUTCOME (N=7,020) randomized adults with type 2 diabetes and established CVD to empagliflozin 10 mg, 25 mg, or placebo on top of standard care. At a median 3.1 years, empagliflozin reduced the primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% relative to placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority, P=0.04 for superiority) [2]. Cardiovascular death specifically fell 38%. Hospitalization for heart failure dropped 35%.

What UKPDS Showed for Metformin

Metformin's cardiovascular story comes from UKPDS 34 (N=753 overweight patients with newly diagnosed type 2 diabetes). Over 10.7 years, metformin-allocated patients showed a 39% reduction in MI risk compared with conventional diet therapy (P=0.01) and a 36% reduction in all-cause mortality [3]. Those are meaningful numbers, but the population was newly diagnosed with no established CVD, making direct comparison to EMPA-REG OUTCOME populations problematic.

The 2023 ADA Standards of Care state: "In patients with type 2 diabetes and established CVD or high CVD risk, an SGLT2 inhibitor or GLP-1 RA with proven CVD benefit is recommended independent of A1C." Metformin is not in that first recommendation tier for established CVD patients [4].

Practical Prescribing Point

If a patient presents with a recent MI, known coronary artery disease, or peripheral arterial disease and is not yet on an SGLT2 inhibitor, empagliflozin should be added regardless of whether metformin is already prescribed.

Heart Failure: Empagliflozin Has a Dedicated Indication

Empagliflozin is FDA-approved for reducing cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of ejection fraction. The EMPEROR-Reduced trial (N=3,730, HFrEF) showed empagliflozin 10 mg reduced the composite of CV death or HHF by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) [5]. EMPEROR-Preserved (N=5,988, HFpEF) showed similar benefit for HFpEF, an area where few therapies have succeeded [6].

Metformin carries no dedicated heart failure indication. Historically it was listed as a relative contraindication in heart failure over concern for lactic acidosis in low-perfusion states, though that warning was largely removed from U.S. Labeling in 2016. Observational data suggest metformin may be safe and possibly beneficial in stable, compensated heart failure, but no randomized trial has established a mortality benefit in this population.

Volume Status and Diuretic Combination

Empagliflozin produces modest osmotic diuresis. In patients already on loop diuretics, this effect can reduce diuretic requirements. A smaller volume load may translate to fewer HHF events. Metformin has no diuretic or preload-reducing property.

Chronic Kidney Disease: A Nuanced Trade-Off

This is where the comparison gets most clinically demanding.

Metformin Restrictions by eGFR

The FDA 2016 label update restricts metformin based on eGFR:

• eGFR 45 to 60 (Stage 3a/3b): use with caution, monitor renal function every 3 to 6 months
• eGFR 30 to 45: do not start; consider stopping if eGFR falls to this range in a patient already on metformin
• eGFR <30: contraindicated

The mechanism is risk of metformin accumulation and subsequent lactic acidosis when renal clearance is impaired. In clinical practice, many patients with eGFR 45 to 60 tolerate metformin well, but prescribers must monitor proactively [7].

Empagliflozin in CKD

Empagliflozin loses glycemic efficacy as eGFR declines because fewer functional nephrons are available for SGLT2 blockade. Glycemic contribution becomes minimal below eGFR 45. The renal protection benefit, however, persists at lower eGFR values.

The EMPA-KIDNEY trial (N=6,609, eGFR 20 to 45 or proteinuria) found empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [8]. Patients with eGFR as low as 20 were enrolled. The FDA expanded empagliflozin's label in 2023 to include reduction of eGFR decline, ESKD, CV death, and hospitalization in CKD.

Choosing Between Them in CKD

At eGFR 45 to 60: both agents can be used, though metformin requires monitoring and empagliflozin provides renal protective benefit beyond glycemic control.

At eGFR 30 to 44: empagliflozin for renal and cardiovascular protection; metformin should generally be stopped or not started.

At eGFR <30: neither agent is appropriate for glycemic control in this range; empagliflozin is contraindicated for glycemic use, and metformin is contraindicated entirely.

Elderly Patients (Age 65 and Older)

Both drugs require specific consideration in older adults, but for different reasons.

Metformin in Older Adults

Metformin is generally well tolerated in elderly patients with preserved renal function. GI side effects (nausea, diarrhea) affect roughly 20 to 30% of patients and are more pronounced at initiation. Starting at 500 mg with the evening meal and titrating slowly reduces GI burden. Vitamin B12 deficiency occurs in approximately 5.8% of long-term metformin users and should be screened annually in older adults given overlap with neuropathy risk [9].

Hypoglycemia is not a concern with metformin monotherapy, which matters in elderly patients where hypoglycemia carries higher risks of falls and arrhythmias.

Empagliflozin in Older Adults

Empagliflozin carries specific risks that are amplified in elderly patients:

Genitourinary infections (UTIs and genital mycotic infections) are more frequent with SGLT2 inhibitors. Postmenopausal women and uncircumcised men are at highest risk. Genital mycotic infections occurred in 10.4% of women on empagliflozin in EMPA-REG OUTCOME vs 1.8% placebo.

Volume depletion and orthostatic hypotension are meaningful concerns. Empagliflozin's osmotic diuresis can compound the effect of concurrent antihypertensives or diuretics in a patient with reduced thirst sensation.

Diabetic ketoacidosis (DKA) risk, while low overall, is higher in older patients with prolonged fasting, surgical procedures, or concurrent illness. "Euglycemic DKA" with glucose levels below 250 mg/dL is a recognized SGLT2 inhibitor complication that can be missed if glucose-based criteria are the only trigger for testing.

Fracture risk with empagliflozin is a consideration raised for the class, though EMPA-REG OUTCOME did not show a significant increase in fractures with empagliflozin specifically [2].

A Simple Framework for Elderly Patients

For an otherwise healthy 72-year-old with eGFR above 60, no established CVD, and no heart failure: metformin remains first-line. For a 75-year-old with CKD stage 3b, prior hospitalization for decompensated heart failure, and eGFR 38: empagliflozin at 10 mg for cardio-renal protection, with no metformin.

Obesity and Metabolic Syndrome

Weight loss is a secondary but clinically meaningful benefit of both drugs. Neither is a weight-loss drug in the class of semaglutide or tirzepatide, but the difference between them is relevant in patients where even modest weight reduction improves metabolic outcomes.

Weight Data Compared

Empagliflozin produces roughly 2 to 3 kg of weight loss through glucosuria (approximately 60 to 90 g of glucose excreted per day, representing 240 to 360 kcal). The loss is predominantly fat mass with modest lean mass reduction.

Metformin produces approximately 1 to 2 kg weight loss relative to comparators, largely through appetite reduction mediated by GLP-1 elevation and possible hypothalamic effects. The Diabetes Prevention Program (DPP, N=3,234) showed metformin reduced diabetes incidence by 31% compared to placebo over 2.8 years, with a mean weight loss of 2.1 kg vs 0.1 kg placebo [10].

For a patient with type 2 diabetes and BMI above 35 who cannot yet access a GLP-1 receptor agonist, combining both agents provides additive weight and glycemic benefit. Neither agent causes hypoglycemia as monotherapy, making the combination inherently safe from that perspective.

Blood Pressure

Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg through natriuresis, a benefit metformin does not share. In a patient with both hypertension and type 2 diabetes, this secondary effect of empagliflozin can reduce polypharmacy pressure.

Patients With Fatty Liver Disease (MASLD/NAFLD)

Non-alcoholic fatty liver disease affects approximately 55 to 70% of patients with type 2 diabetes. Both agents have hepatic effects, though neither is currently FDA-approved for liver disease specifically.

Metformin suppresses hepatic glucose output and may reduce hepatic fat content in some patients, but evidence from liver biopsy studies has been inconsistent. A Cochrane review found insufficient high-quality evidence to support metformin as a treatment for NASH histology [11].

Empagliflozin has shown more consistent reductions in hepatic fat fraction on MRI-PDFF in small trials. A 24-week trial (N=84) found empagliflozin 10 mg reduced liver fat by 2.0 percentage points vs placebo (P<0.001), along with reductions in liver stiffness and ALT [12]. Larger outcomes trials specifically in MASLD are ongoing.

Type 2 Diabetes Newly Diagnosed: Starting From Zero

The ADA Standards of Care 2024 recommend metformin as the preferred initial agent for most patients newly diagnosed with type 2 diabetes who do not have established CVD, CKD, or heart failure and who are primarily seeking glycemic control at low cost [4].

The argument for starting with empagliflozin de novo outside high-risk populations is weaker for two reasons: cost and the absence of a dedicated outcomes trial in CV-naive patients showing mortality benefit.

For a 45-year-old with newly diagnosed type 2 diabetes, A1C of 7.8%, no CVD, eGFR 85, and no heart failure: metformin 500 mg twice daily with food is appropriate first-line therapy. Titrate to 1,000 mg twice daily over 4 to 8 weeks as tolerated.

When to Add Empagliflozin Early

Adding empagliflozin at diagnosis or within 3 months makes clinical sense if:

• A1C is above 9% and the patient needs more than one agent to reach target
• The patient has risk factors for CVD that make future events likely (10-year ASCVD risk above 20%)
• Weight-bearing is a clinical priority and GLP-1 agonists are not accessible

The combination of metformin plus empagliflozin is well-studied, well-tolerated, and available as a fixed-dose combination (Synjardy: empagliflozin/metformin) [13].

Switching Jardiance to Metformin (and Vice Versa)

Switching rather than combining is occasionally the right call. Understanding when each direction makes sense prevents clinical errors.

Switching From Jardiance to Metformin

Common reasons include: loss of insurance coverage for branded empagliflozin, resolution of the specific risk factor that drove SGLT2 use (rare), or patient intolerance to genitourinary infections.

When switching, overlap both drugs for at least 2 to 4 weeks if glycemic control permits, or accept that A1C may temporarily worsen if empagliflozin is stopped abruptly. Start metformin at 500 mg with the largest meal to minimize GI side effects and titrate over 4 weeks. Check eGFR before starting metformin if it has not been measured recently.

Switching From Metformin to Jardiance

This direction is less common since most patients on empagliflozin are also on metformin. Situations where it occurs: eGFR declining into the 30 to 44 range, lactic acidosis concern (rare), or GI intolerance to metformin despite extended-release formulation.

Stop metformin when eGFR drops below 30 or approaches 30 with a downward trend. Start empagliflozin 10 mg daily in the morning. Remind patients about genital hygiene, increased urination especially in the first 1 to 2 weeks, and to hold the drug before any planned surgical procedure with expected fasting longer than 12 hours.

Pregnancy, Lactation, and Reproductive-Age Women

Neither empagliflozin nor metformin is approved for use in pregnancy.

Metformin is used off-label in gestational diabetes and polycystic ovary syndrome, with a substantial body of observational data suggesting fetal safety, though the FDA category language no longer applies post-2015 labeling changes. The MiG trial (N=751) found metformin was not inferior to insulin for gestational diabetes outcomes, with less maternal weight gain [14].

Empagliflozin is classified Pregnancy Category not applicable under the new system, but animal data show renal pelvic and tubule dilatation in fetuses exposed during late organogenesis. The drug should be discontinued once pregnancy is detected. Data in lactation are absent; the molecular weight and renal excretion profile suggest breast milk transfer is possible.

For reproductive-age women with type 2 diabetes planning pregnancy: transition off empagliflozin before conception; metformin is the better-studied option if oral therapy is continued into early pregnancy under specialist guidance.

Cost and Access Considerations

Metformin is among the least expensive drugs in all of medicine. Generic metformin hydrochloride 1,000 mg twice daily costs under $10 per month at major pharmacy chains with GoodRx pricing. Extended-release formulations run $15 to 30 per month.

Branded Jardiance retails at approximately $550 to 620 per month without insurance. Eli Lilly's patient assistance program (Lilly Cares) covers eligible patients below income thresholds. A $35/month Lilly co-pay card is available for commercially insured patients. For Medicare Part D enrollees, the $2,000 out-of-pocket cap under the Inflation Reduction Act beginning 2025 significantly reduces annual cost exposure for empagliflozin.

Access should be part of every prescribing conversation. A patient who cannot consistently afford Jardiance gets no cardiovascular or renal benefit from a prescription that sits unfilled.

Drug Interactions and Monitoring Differences

Both drugs have manageable interaction profiles, but the relevant parameters differ.

Metformin interactions center on drugs that impair renal clearance: contrast media (hold for 48 hours before and after iodinated contrast in patients with eGFR <60), topiramate (raises metformin plasma levels), and carbonic anhydrase inhibitors. Cationic drugs (trimethoprim, vancomycin) compete with OCT2-mediated renal secretion and may raise metformin levels.

Empagliflozin has no major cytochrome P450 interactions. The main clinical concern is additive volume depletion with diuretics, NSAIDs, and ACE inhibitors. Monitoring priorities: eGFR and urine albumin-to-creatinine ratio at baseline and annually, hemoglobin/hematocrit (modest hemoconcentration is common), and genital symptoms.

Routine labs with metformin: eGFR at baseline and at least annually, serum B12 every 1 to 2 years in long-term users given the 5.8% depletion rate.